Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lipid-based antifungal agents: Current status
Autore:
Arikan, S; Rex, JH;
Indirizzi:
Hacettepe Univ, Sch Med, Dept Microbiol & Clin Microbiol, Mycol Unit, TR-06100 Ankara, Turkey Hacettepe Univ Ankara Turkey TR-06100 ycol Unit, TR-06100 Ankara, Turkey Univ Texas, Sch Med, Dept Internal Med,Div Infect Dis, Ctr Study Emerging & Reemerging Pathogens, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 emerging Pathogens, Houston, TX 77030 USA
Titolo Testata:
CURRENT PHARMACEUTICAL DESIGN
fascicolo: 5, volume: 7, anno: 2001,
pagine: 393 - 415
SICI:
1381-6128(200103)7:5<393:LAACS>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
LIPOSOMAL AMPHOTERICIN-B; INVASIVE FUNGAL-INFECTIONS; MARROW TRANSPLANT RECIPIENTS; PERSISTENTLY GRANULOCYTOPENIC RABBITS; CANDIDA-KRUSEI INFECTION; IN-VITRO ACTIVITY; COLLOIDAL DISPERSION; NEUTROPENIC MICE; SYSTEMIC CANDIDIASIS; FAT EMULSION;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
151
Recensione:
Indirizzi per estratti:
Indirizzo: Arikan, S Hacettepe Univ, Sch Med, Dept Microbiol & Clin Microbiol, Mycol Unit, TR-06100 Ankara, Turkey Hacettepe Univ Ankara Turkey TR-06100 TR-06100 Ankara, Turkey
Citazione:
S. Arikan e J.H. Rex, "Lipid-based antifungal agents: Current status", CUR PHARM D, 7(5), 2001, pp. 393-415

Abstract

Immunocompromised patients are well known to be predisposed to developing invasive fungal infections. These infections are usually difficult to diagnose and more importantly, the resulting mortality rate is high. The limitednumber of antifungal agents available and their high rate of toxicity are the major factors complicating the issue. However, the development of lipid-based formulations ol existing antifungal agents has opened a new era in antifungal therapy. The best examples are the lipid-based amphotericin B preparations, amphotericin B lipid complex (ABLC; Abelcet(R)), amphotericin B colloidal dispersion (ABCD; Amphotec(R) or Amphocil(R)), and liposomal amphotericin B (AmBisome(R)). These formulations have shown that antifungal activity is maintained while toxicity is reduced. This progress is followed bythe incorporation of nystatin into liposomes. Liposomal nystatin formulation is under development and studies of it have provided encouraging data. Finally, lipid-based formulations of hamycin, miconazole, and ketoconazole have been developed but remain experimental. Advances in technology of liposomes and other lipid formulations have provided promising new tools for management of fungal infections.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 14:43:08